Hospital for Special Surgery

Running trials

• Recruiting

  Safety and Efficacy of ONT01 in Lupus

  NCT07107659· Early phase 1· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

  NCT07176546· Phase 2/3· Source

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Source

• Recruiting

  RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  NCT06455085· Source

• Active, not recruiting

  A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06470048· Phase 2· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Source

• Recruiting

  A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT06290141· Phase 3· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Source

• Enrolling by invitation

  A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

  NCT06518668· Phase 1· Source

• Recruiting

  Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

  NCT05799378· Phase 3· Source

• Recruiting

  The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

  NCT05538208· Phase 2· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Source

• Recruiting

  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Phase 4· Source

• Enrolling by invitation

  G7 Dual Mobility With Vivacit-E or Longevity PMCF

  NCT05548972· Source

• Recruiting

  VIBRANT: VIB4920 for Active Lupus Nephritis

  NCT05201469· Phase 2· Source

• Recruiting

  Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

  NCT05782335· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Source

• Active, not recruiting

  Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

  NCT00775476· Phase 2· Source

• Active, not recruiting

  Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

  NCT05270668· Phase 2· Source

• Active, not recruiting

  Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

  NCT05218668· Phase 2· Source

• Active, not recruiting

  Chronic Pain in Rheumatoid Arthritis

  NCT05038553· Source

• Active, not recruiting

  Centrally Acting ACE Inhibition in SLE

  NCT04486118· Phase 2· Source

• Recruiting

  RA-PRO PRAGMATIC TRIAL

  NCT04692493· Phase 3· Source

• Active, not recruiting

  INFINITY™ With ADAPTIS™ Technology Study

  NCT04594993· Source

• Active, not recruiting

  Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

  NCT04467983· Phase 4· Source

• Active, not recruiting

  Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

  NCT03844061· Phase 2· Source

• Active, not recruiting

  JOURNEY II XR Safety and Effectiveness PMCF

  NCT03136887· Source

• Active, not recruiting

  A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

  NCT03122522· Phase 2· Source

• Active, not recruiting

  Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

  NCT02682511· Phase 2· Source

• Recruiting

  Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

  NCT02418442· Source

• Recruiting

  Scleroderma Registry & Repository at the Hospital for Special Surgery

  NCT01656447· Source

• Recruiting

  Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

  NCT00198068· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)6 recruiting
• Rheumatoid arthritis4 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• ANCA-associated vasculitis2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Obesity1 recruiting
• Osteoporosis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

  NCT05462522· Phase 1· Source

• Terminated

  COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

  NCT05000216· Phase 2· Source

• Completed

  Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

  NCT03675282· Phase 1/2· Source

• Completed

  Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

  NCT02108860· Phase 3· Source

• Recruiting

  Simple Bone Cysts in Kids

  NCT02193841· Phase 3· Source

• Terminated

  Consortium of Early Arthritis Cohorts USA

  NCT02386527· Source

• Completed

  A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement

  NCT01969188· Source

• Recruiting

  One-Time DNA Study for Vasculitis

  NCT01241305· Source

Trial sites

• Hospital for Special Surgery37 trials
• Hospital for Special Surgery (Data Analysis)1 trial
• Hospital for Special Surgery, New York: Division of Rheumatology1 trial
• Hospital For Special Surgery (Site 4020)1 trial
• Hospital for Special Surgery - Site Number : 84000412 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Rheumatoid arthritis33 works · 9 trials
• Osteoporosis23 works · 2 trials
• Lupus (SLE)22 works · 12 trials
• Systemic sclerosis (scleroderma)22 works · 9 trials
• ANCA-associated vasculitis3 works · 4 trials